Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Published Online: 2019-11-?
Journal: Annals of Oncology•Publisher: Elsevier BV
Authors: A.P. Chen•B.A. Conley•C.L. Arteaga•D. Patton•E. Sharon•E.P. Mitchell•J.A. Zwiebel•K.L. Jhaveri•K.T. Flaherty•L.M. McShane•L.N. Harris•L.V. Rubinstein•P.J. O’Dwyer•P.M. Williams•R.J. Gray•S. Li•S.-W. Luoh•S.R. Hamilton•V. Makker•X.V. Wang
